Stockscreener 앱 받기
21.75
6.76%
1.3982
전일 마감가:
$20.35
열려 있는:
$20.31
하루 거래량:
1.11M
Relative Volume:
1.23
시가총액:
$1.39B
수익:
$9.98M
순이익/손실:
$-154.08M
주가수익비율:
-8.4295
EPS:
-2.58
순현금흐름:
$-159.66M
1주 성능:
+0.35%
1개월 성능:
+9.83%
6개월 성능:
-14.03%
1년 성능:
-44.28%
1일 변동 폭
$20.01
$22.32
1주일 범위
$19.52
$22.32
52주 변동 폭
$14.40
$47.00
Celldex Therapeutics Inc Stock (CLDX) Company Profile
명칭
Celldex Therapeutics Inc
전화
908-200-7500
주소
53 FRONTAGE ROAD, HAMPTON
CLDX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CLDX
Celldex Therapeutics Inc
|
21.71 | 1.39B | 9.98M | -154.08M | -159.66M | -2.58 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.19 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
539.58 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
324.63 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
549.73 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
244.00 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Celldex Therapeutics Inc Stock (CLDX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-04-28 | 개시 | Canaccord Genuity | Buy |
| 2025-03-20 | 개시 | Morgan Stanley | Overweight |
| 2025-02-13 | 개시 | UBS | Buy |
| 2024-10-07 | 개시 | Citigroup | Buy |
| 2024-09-30 | 개시 | Goldman | Neutral |
| 2024-09-27 | 다운그레이드 | Wolfe Research | Outperform → Peer Perform |
| 2024-06-18 | 개시 | Stifel | Buy |
| 2024-06-11 | 개시 | Wolfe Research | Outperform |
| 2023-12-20 | 개시 | TD Cowen | Outperform |
| 2023-11-10 | 업그레이드 | Wells Fargo | Underweight → Equal Weight |
| 2023-08-22 | 개시 | Wells Fargo | Underweight |
| 2021-09-17 | 개시 | Jefferies | Buy |
| 2021-09-10 | 개시 | SVB Leerink | Outperform |
| 2021-07-22 | 개시 | Guggenheim | Buy |
| 2020-02-21 | 개시 | Cantor Fitzgerald | Overweight |
| 2017-08-01 | 재개 | H.C. Wainwright | Buy |
| 2016-11-07 | 개시 | Aegis Capital | Buy |
| 2016-03-08 | 다운그레이드 | Jefferies | Buy → Hold |
| 2016-03-07 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2016-03-07 | 다운그레이드 | Leerink Partners | Outperform → Mkt Perform |
| 2016-03-07 | 다운그레이드 | Wedbush | Outperform → Neutral |
| 2016-03-01 | 개시 | H.C. Wainwright | Buy |
| 2015-08-11 | 재확인 | Brean Capital | Buy |
| 2015-08-11 | 재확인 | Oppenheimer | Outperform |
| 2015-08-11 | 재확인 | ROTH Capital | Buy |
| 2015-06-02 | 재확인 | WBB Securities | Strong Buy |
| 2014-11-17 | 재확인 | ROTH Capital | Buy |
| 2014-03-04 | 재확인 | Oppenheimer | Outperform |
| 2013-07-08 | 재확인 | Cantor Fitzgerald | Buy |
| 2013-03-08 | 재확인 | Cantor Fitzgerald | Buy |
| 2013-02-26 | 재확인 | Oppenheimer | Outperform |
| 2013-01-10 | 재확인 | Cantor Fitzgerald | Buy |
| 2012-10-02 | 재확인 | Oppenheimer | Outperform |
| 2012-09-14 | 재확인 | Cantor Fitzgerald | Buy |
모두보기
Celldex Therapeutics Inc 주식(CLDX)의 최신 뉴스
Celldex stock price target maintained at $50 by H.C. Wainwright - Investing.com Canada
Global Personalized Cancer Vaccine Market | Immunotherapy - openPR.com
Q2 Earnings Estimate for CLDX Issued By Lifesci Capital - Defense World
Celldex Study Finds Most Patients Symptom-Free From Angioedema After One Year; Retail Bulls Stay Guarded - Asianet Newsable
Celldex Therapeutics (NASDAQ:CLDX) Earns “Buy” Rating from HC Wainwright - Defense World
Celldex Presents Data Demonstrating Profound Long Term Improvement In Angioedema In Barzolvolimab Phase 2 Study In Chronic Spontaneous Urticaria At Eaaci 2025 - MarketScreener
Celldex Presents Data Demonstrating Profound Long Term - GlobeNewswire
Celldex Presents Data Demonstrating Profound Long Term Improvement in Angioedema in Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria at EAACI 2025 - GlobeNewswire Inc.
Celldex Therapeutics (CLDX) Maintains "Buy" Rating with $50 Targ - GuruFocus
Celldex Therapeutics’ SWOT analysis: barzolvolimab stock shows promise amid challenges By Investing.com - Investing.com South Africa
Celldex Therapeutics’ SWOT analysis: barzolvolimab stock shows promise amid challenges - Investing.com
Celldex Therapeutics Inc (CLDX) Stock: A Comprehensive 52-Week Review - investchronicle.com
Celldex shares jump on impressive skin disorder drug data By Investing.com - Investing.com Canada
Celldex Therapeutics (CLDX) Maintains "Buy" Rating with $50 Target | CLDX Stock News - GuruFocus
Rein Therapeutics study on clinical hold; Beam updates sickle cell therapy data - Endpoints News
Unusual Machines, Celldex Therapeutics, RH And Other Big Stocks Moving Higher On Friday - Benzinga
Celldex stock maintains Overweight rating on promising CSU therapy results By Investing.com - Investing.com Canada
Forecasting The Future: 8 Analyst Projections For Celldex Therapeutics - Benzinga
Celldex Presents Unprecedented 76 Week Results from - GlobeNewswire
Transcript : Celldex Therapeutics, Inc.Special Call - marketscreener.com
Celldex Presents Phase 2 Study In Chronic Spontaneous Urticaria At Eaaci Congress 2025 - marketscreener.com
Celldex (CLDX) Unveils Promising Data for Barzolvolimab in Treating Chronic Urticaria | CLDX Stock News - GuruFocus
Breakthrough: Celldex CSU Drug Maintains Complete Response 7 Months After Treatment Ends - Stock Titan
Celldex stock rating reiterated at Buy by Canaccord ahead of data release - Investing.com Nigeria
One Celldex Therapeutics Insider Raised Stake By 40% In Previous Year - simplywall.st
Eric Sprott buying at Silver Storm Mining (SVRS) - The Globe and Mail
Analysts Set Expectations for CLDX FY2026 Earnings - Defense World
Celldex Announces Upcoming Presentations of Barzolvolimab Phase 2 Data in Chronic Spontaneous Urticaria at EAACI 2025 Congress - GlobeNewswire
Groundbreaking 76-Week Chronic Urticaria Treatment Data: Celldex's Barzolvolimab Results Coming to EAACI - Stock Titan
Celldex Therapeutics appoints new board member By Investing.com - Investing.com South Africa
Celldex Therapeutics Appoints Denice Torres To Board - citybiz
Celldex Therapeutics appoints new board member - Investing.com
Celldex Approves Equity Plan Amendment and Elects New Director - TipRanks
Celldex Therapeutics Announces Election of Denice Torres to its Board of Directors - Yahoo Finance
Prurigo Nodularis Pipeline 2025: FDA Updates, Therapy - openPR.com
MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. Boosts Stake in Celldex Therapeutics, Inc. (NASDAQ:CLDX) - Defense World
Celldex Therapeutics’ SWOT analysis: barzolvolimab stock poised for growth By Investing.com - Investing.com South Africa
Global Cholera Vaccines Market in 2025-2032 Detailed Study - openPR.com
Celldex Therapeutics’ SWOT analysis: barzolvolimab stock poised for growth - Investing.com India
BNP Paribas Financial Markets Raises Position in Celldex Therapeutics, Inc. (NASDAQ:CLDX) - Defense World
Celldex Therapeutics Reports Increased Losses Amid R&D Expansion - TipRanks
Morgan Stanley Cuts Celldex Therapeutics (NASDAQ:CLDX) Price Target to $43.00 - Defense World
UBS Group Cuts Celldex Therapeutics (NASDAQ:CLDX) Price Target to $38.00 - Defense World
The Goldman Sachs Group Cuts Celldex Therapeutics (NASDAQ:CLDX) Price Target to $31.00 - Defense World
Hsbc Holdings PLC Takes $233,000 Position in Celldex Therapeutics, Inc. (NASDAQ:CLDX) - Defense World
Celldex Therapeutics Q1 2025 Earnings: EPS of ($0.81) Misses Est - GuruFocus
UBS Lowers Price Target for Celldex Therapeutics (CLDX) to $38 | - GuruFocus
First Trust Advisors LP Trims Holdings in Celldex Therapeutics, Inc. (NASDAQ:CLDX) - Defense World
H.C. Wainwright cuts Celldex stock price target to $50 from $80 - Investing.com Nigeria
Celldex Therapeutics (CLDX): Analyst Lowers Price Target But Mai - GuruFocus
Morgan Stanley Updates Price Target for Celldex Therapeutics (CL - GuruFocus
Celldex Therapeutics Inc (CLDX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.56%
0.72%
자본화:
|
볼륨(24시간):